Cargando…
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
OBJECTIVES: Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. METHODS: A randomised, double-b...
Autores principales: | He, Jing, Zhang, Ruijun, Shao, Miao, Zhao, Xiaozhen, Miao, Miao, Chen, Jiali, Liu, Jiajia, Zhang, Xiaoying, Zhang, Xia, Jin, Yuebo, Wang, Yu, Zhang, Shilei, Zhu, Lei, Jacob, Alexander, Jia, Rulin, You, Xujie, Li, Xue, Li, Chun, Zhou, Yunshan, Yang, Yue, Ye, Hua, Liu, Yanying, Su, Yin, Shen, Nan, Alexander, Jessy, Guo, Jianping, Ambrus, Julian, Lin, Xin, Yu, Di, Sun, Xiaolin, Li, Zhanguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937406/ https://www.ncbi.nlm.nih.gov/pubmed/31537547 http://dx.doi.org/10.1136/annrheumdis-2019-215396 |
Ejemplares similares
-
3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
por: Zhao, Ming, et al.
Publicado: (2023) -
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019) -
Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study
por: Tian, Jingru, et al.
Publicado: (2023) -
Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015) -
A CD8 T Cell/Indoleamine 2,3-Dioxygenase Axis Is Required for Mesenchymal Stem Cell Suppression of Human Systemic Lupus Erythematosus
por: Wang, Dandan, et al.
Publicado: (2014)